Based on these findings (that administration of GLP-1R agonists remarkably attenuated DN progression both in diabetic animal and patients [13,14]), activation of GLP-1R-dependent responses is a promising target for DN therapy. Here, GLP1R is linked to liver dysplastic nodule.